Pulmonary Hypertension, Familial Persistent, of the NewbornPhase 3NCT01720524
A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
A Phase 3 study testing iv sildenafil in people with Pulmonary Hypertension, Familial Persistent, of the Newborn, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 42 sites in 12 countries.
Trial summary
This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn. Read more about this study
- Who is it for?
- Ages 0 to 4 days
- Conditions the study is for
- Pulmonary Hypertension, Familial Persistent, of the Newborn
- What is being tested?
- iv sildenafil
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 59 participants
- Where
- 42 sitesin 12 countries
- Study dates
- 5 Aug 2013to 28 Sep 2020
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 4 days
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Neonates with persistent pulmonary hypertension of the newborn
- Age <=96 hours and >=34 weeks gestational age
- Oxygenation Index >15 and <60
- Concurrent treatment with inhaled nitric oxide and >=50% oxygen
Who cannot join
- Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation
- Expected duration of mechanical ventilation <48 hours
- Profound hypoxemia
- Life-threatening or lethal congenital anomaly
Trial locations and contacts
42 sites in 12 countries.
42 sites in 12 countries
United States20 sites
Fairview Hospital
Cleveland, Ohio, 44111
Cleveland Clinic
Cleveland, Ohio, 44195
Duke University Medical Center (DUMC)
Durham, North Carolina, 27710
Indiana University Health Methodist Hospital
Indianapolis, Indiana, 46202
Riley Hospital for Children at IU Health
Indianapolis, Indiana, 46202
Sydney and Lois Eskenazi Hospital
Indianapolis, Indiana, 46202
Children's Mercy Hospitals & Clinics
Kansas City, Missouri, 64108
Arkansas Children's Hospital
Little Rock, Arkansas, 72202
Vanderbilt Children's Hospital
Nashville, Tennessee, 37232
OU Follow-Up Program, PREMIEr Clinic, Children's Hospital
Oklahoma City, Oklahoma, 73104
OU Neonatal Intensive Care Unit at Children's Hospital
Oklahoma City, Oklahoma, 73104
The University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
University of California Davis Medical Center
Sacramento, California, 95817
University of California Davis
Sacramento, California, 95817
University of California Davis Medical Center
Sacramento, California, 95825
Seattle Children's Research Institute
Seattle, Washington, 98101
Seattle Childrens Hospital
Seattle, Washington, 98105
Henry Zarrow Neonatal Intensive Care Unit, Children's Hospital at Saint Francis
Tulsa, Oklahoma, 74136
Warren Cancer Research Foundation
Tulsa, Oklahoma, 74136
Children´s National Medical Center
Washington D.C., District of Columbia, 20010
France5 sites
Centre Hospitalier et Regional de Lille - Hopital Jeanne de Flandre
Lille, 59037
Centre Hospitalier et Régional de Lille,
Lille, 59037
Hôpital de la Conception Assistance Publique-Hôpitaux de Marseille
Marseille, 13385
CHU Robert Debré
Paris, 75019
Hopital NECKER - Enfants Malades
Paris, 75743
United Kingdom4 sites
St. Michael's Hospital
Bristol, BS2 8EG
Leicester Royal Infirmary
Leicester, LE1 5WW
Glenfield Hospital, University Hospitals of Leicester NHS Trust
Leicester, LE3 9QP
Great Ormond Street Hospital NHS Foundation Trust
London, WC1N 3JH
Belgium2 sites
Universitair Ziekenhuis Antwerpen
Edegem, 2650
UZ Gent
Ghent, 9000
Denmark2 sites
Aarhus Universitetshospital, Skejby
Aarhus N, 8200
Neonatalklinikken Rigshospitalet, 5024
Copenhagen Ø, 2100
Netherlands2 sites
Radboud University Nijmegen Medical Centre
Nijmegen, 6525 GA
Erasmus MC, Sophia Children's hospital
Rotterdam, 3015 CN
Spain2 sites
Hospital Sant Joan de Deu
Esplugues de Llobregat, Barcelona / Spain, 08950
Hospital General Universitario Gregorio Marañon
Madrid, 28007
About this study
Official title: A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT
This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.
- Being tested
- placebo, iv sildenafil
- Keywords
- persistent pulmonary hypertension, newborn, neonates, iv sildenafil, hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn
- Medical subject headings
- Persistent Fetal Circulation Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
placeboDrug
IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
iv sildenafilDrug
Also called revatio
loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.
| Study group | Role | What they receive |
|---|---|---|
| placebo | Placebo comparator | iv placebo of normal saline or 10% dextrose Receives: Drug: placebo |
| sildenafil | Experimental | Active study drug Receives: Drug: iv sildenafil |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure
Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.
Measured: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Treatment Failure Rate
Treatment failure rate was defined as percentage of participants who needed additional treatment targeting PPHN, needed ECMO, or died during the study.
Measured: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Secondary outcomes (30)
Time From Initiation of Intravenous (IV) Study Drug to Final Weaning of Mechanical Ventilation
Time in days, from initiation of IV study drug to final weaning of mechanical ventilation among participants achieving final weaning of mechanical ventilation for PPHN was evaluated. Kaplan-Meier method was used for estimation. For participants with mechanical ventilation beyond 336 hours (14 days) from initiation of IV study drug, data was censored at 14 days.
Measured: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Time From Initiation of Intravenous (IV) Study Drug to First Treatment Failure
Time in days, from initiation of IV study drug to first treatment failure (defined as need for additional treatment targeting PPHN, need for ECMO, or death) for participants with treatment failure was evaluated. Kaplan-Meier method was used for estimation. For participants without treatment failure by the endpoint assessment date, data was censored at the endpoint assessment date.
Measured: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Percentage of Participants With Individual Components of Treatment Failure
Percentage of participants with individual components of treatment failure (need to start additional treatment targeting PPHN, need to start ECMO, or death) were evaluated. Some participants could have had multiple qualifying events for treatment failure.
Measured: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Change From Baseline in Oxygenation Index (OI) at Hours 6, 12 and 24 Post-Infusion
Oxygenation index was calculated as the product of fraction of inspired oxygen (FiO2) and mean airway pressure divided by partial pressure of oxygen dissolved in arterial blood (PaO2) [(FiO2*mean airway pressure)/PaO2] measured in centimeter of water per millimeter of mercury (cmH2O/mmHg). FiO2 is the measure of oxygen concentration that is breathed. Mean airway pressure is defined as an average of the airway pressure throughout the respiratory cycle. PaO2 is the measure of oxygen level dissolved in the arterial blood.
Measured: Baseline, Hours 6, 12 and 24 after start of infusion
Change From Baseline in Differential Saturation at Hours 6, 12 and 24 Post-Infusion
Differential oxygenation saturation is a simple way to detect the right-to left shunting at ductus arteriosus using 2 pulse oximeters. It is the difference between pre-ductal and post-ductal sites pulse oxygen saturation (SpO2). Where, pre-duct refers to right upper extremity and post-duct refers to lower limb. Oxygenation saturation is measured as percentage of hemoglobin binding sites occupied by oxygen in the blood.
Measured: Baseline, Hours 6, 12 and 24 after start of infusion
Change From Baseline in Ratio of Partial Pressure of Oxygen in Arterial Blood to Fraction of Inspired Oxygen (P/F) at Hours 6, 12 and 24
The ratio of partial pressure of arterial oxygen to fraction of inspired oxygen is a ratio between the oxygen level in the arterial blood and the oxygen concentration that is breathed. It helps to determine the degree of any problems with how the lungs transfer oxygen to the blood.
Measured: Baseline, Hours 6, 12 and 24 after start of infusion
Maximum Plasma Concentration (Cmax) of Sildenafil and Its Metabolite
Cmax was obtained for Sildenafil and its major metabolite UK-103,320.
Measured: Loading dose, Day 1: prior to the start of infusion, 5, 30 minutes after end of loading infusion; Maintenance dose: 48 to 72, 96 to 120 hours during infusion and immediately prior to end of maintenance infusion (up to maximum on Day 14)
Total Plasma Clearance (CL) of Sildenafil and Its Metabolite
CL is volume of the body fluid/ plasma from which the drug or the metabolite is completely removed per unit time. CL was obtained for Sildenafil and its major metabolite UK-103,320.
Measured: Loading dose: prior to the start of infusion, 5, 30 minutes after end of loading infusion on Day 1; Maintenance dose: between 48 to 72, 96 to 120 hours during infusion and immediately prior to end of infusion on Day 1
Central Volume of Distribution (Vc) of Sildenafil and Its Metabolite
Vc is the hypothetical volume into which a drug or a metabolite initially distributes upon administration. It was determined by using a population-based analysis, non-linear mixed-effects modeling (NONMEM), version 7.4.0. Vc was calculated for Sildenafil and its major metabolite, UK-103,320.
Measured: Loading dose: prior to the start of infusion, 5, 30 minutes after end of loading infusion on Day 1; Maintenance dose: between 48 to 72, 96 to 120 hours during infusion and immediately prior to end of infusion on Day 1
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent are events between first infusion of study drug and up to 31 days after end of study drug infusion (up to 45 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.
Measured: Baseline up to 31 days after end of study drug infusion (up to 45 days)
Number of Treatment-Emergent Adverse Events (AEs) According to Severity
AE: untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent are events between first infusion of study drug and up to 31 days after end of study drug infusion (up to 45 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. Severity criteria: mild=did not interfere with subject's usual function; moderate=interfered to some extent with participant's usual function and severe=interfered significantly with participant's usual function. Missing baseline severities were imputed as mild.
Measured: Baseline up to 31 days after end of study drug infusion (up to 45 days)
Number of Participants With Laboratory Abnormalities
Criteria for laboratory values: Hematology: hemoglobin, hematocrit, red blood cell count <0.8*lower limit of normal (LLN), platelets<0.5*LLN, >1.75*upper limit of normal (ULN), white blood cells count <0.6*LLN, >1.5*ULN; Liver function: total and direct bilirubin >1.5*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase >3.0*ULN, total protein <0.8*LLN, >1.2*ULN; Renal function: blood urea nitrogen, creatinine >1.3*ULN; Electrolytes: sodium <0.95*LLN, >1.05*ULN, potassium, chloride, calcium, bicarbonate (venous) <0.9*LLN, >1.1*ULN.
Measured: Up to 14 days from initiation of study drug infusion
Part B: Composite Scores of Cognitive, Language, and Motor Developmental Progress of Participants as Assessed by Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)
Bayley-III assesses infant and toddler development across five domains: cognitive, language, motor, social-emotional (SE), and adaptive behavior (AB). Assessments of the cognitive, language, and motor domains conducted using items administered to the child; assessments of the SE and AB domains conducted using the primary caregiver's responses to a questionnaire. Score ranges: cognitive scale 0-91, language scale 0-97 and motor scale 0-132, where higher scores indicated better cognitive function, communication and motor skills respectively. Raw scores of cognitive, language and motor domains were converted to composite scores. Composite scores of cognitive, language and motor developmental scales ranged from a scale of 40 to 160, where higher score indicated stronger skills and abilities. In this outcome measure composite scores for infants and toddlers were reported at month 12 and 24.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Composite Scores of Social-Emotional and Adaptive Behavior Questionnaire as Assessed by Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)
The Bayley-III assesses infant and toddler development across five domains: cognitive, language, motor, social-emotional (SE), and adaptive behavior (AB). Assessments of the cognitive, language, and motor domains conducted using items administered to the child; assessments of the SE and AB domains conducted using the primary caregiver's responses to a questionnaire. The questionnaire comprises the SE scale (35 items) and the AB scale (241 items). Raw scores of SE and AB were converted to composite scores. Composite scores for SE and AB scale ranged from 40 to 160, where higher scores indicated better social-emotional skills and adaptive behavior in child. In this outcome measure composite scores for parent/caregiver were reported at month 24.
Measured: Month 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Number of Participants With Eye Movement Disorders as Assessed by Eye Examination
Standard age-appropriate ophthalmological examinations were used to assess eye movement disorders (presence of amblyopia, strabismus, and nystagmus) at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to eye movement disorder categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Visual Acuity of Verbal Participants as Assessed by Ophthalmological Assessment
Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children able of verbal interaction) through visual acuity chart (VAC) quantitative, counting finger (CF), hand motion (HM), light perception (LP), no light perception (NLP) and missing at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual acuity categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Visual Acuity of Non-Verbal Participants as Assessed by Ophthalmological Assessment
Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children unable of verbal interaction) through fixates and follows (included central, steady and maintained), light perception (wince to light), no light perception, and missing at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual acuity categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Visual Acuity of Verbal Participants as Assessed by LogMAR Through Visual Acuity Chart
Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children able of verbal interaction) at month 12 and 24. Visual acuity (VA) of verbal children was assessed for each eye using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal, logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Visual Status of Participants With Abnormality as Assessed by Eye Examination of the Anterior and Posterior Segments
Standard age-appropriate ophthalmological examinations were used to assess examination of anterior and posterior chamber for abnormality in lids, conjunctiva, cornea, anterior chamber, lens, iris, pupil, extraocular muscle movement and eye movements at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual status categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Behavior Hearing Assessment Through Pure Tone Audiometry Test
Audiological evaluations of participants were recorded and reported using behavior hearing assessment through pure tone audiometry test which includes participants with normal, abnormal, incomplete/inconclusive behavior at month 12 and 24.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Bone Conduction Through Pure Tone Audiometry Test
Audiological evaluations of participants were recorded and reported by bone conduction assessment through pure tone audiometry test which included participants with sensorineural hearing loss, conductive hearing loss, mixed hearing loss, neural, and unspecified at month 12 and 24. Rows according to bone conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Air Conduction Via Phones/Headphones Through Pure Tone Audiometry Test
Audiological evaluations of participants were recorded and reported by air conduction via phones/headphones through pure tone audiometry test which included participants with hearing loss ranged from less than or equal to (<=) 20 decibel hearing loss (DB HL), 21-40 DB HL, 41-70 DB HL, 71-90 DB HL, greater than (>) 90 DB HL or no response, and missing at frequencies ranged from 500 Hertz (Hz) to 8000 Hz at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately. Rows according to air conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Air Conduction Via Soundfield Through Pure Tone Audiometry Test
Audiological evaluations of participants were recorded and reported by air conduction via soundfield through pure tone audiometry test which included participants with hearing loss ranged from <=20 DB HL, 21-40 DB HL, 41-70 DB HL, 71-90 DB HL, >90 DB HL or no response, and missing at frequencies ranged from 500 Hz to 4000 Hz at month 12 and 24. Rows according to air conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Tympanometry Assessment (Peak Pressure) Through Immittance Audiometry Test
Audiological evaluations of participants were recorded and reported by tympanometry assessment through immittance audiometry test which included participants with peak pressure signs (+) and (-) at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Tympanometry Assessment (Static Acoustic Admittance) Through Immittance Audiometry Test
Audiological evaluations of participants were recorded and reported by tympanometry assessment through immittance audiometry test which included participants with static acoustic admittance at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Ipsilateral Stapedial Reflex Through Immittance Audiometry Test
Audiological evaluations of participants were recorded and reported by ipsilateral stapedial reflex through immittance audiometry test which included participants with presence of ipsilateral stapedial reflex at frequencies ranged from 500 Hz to 2000 Hz at month 12 and 24. Ipsilateral stapedial reflex measures are used to assess the neural pathway surrounding the stapedial reflex, which occurs in response to a loud sound (70 to 90 decibel above threshold). In this outcome measure, data have been reported for right and left ear separately.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Transient Evoked Emission Through Otoacoustic Emissions Assessment
Audiological evaluations of participants were recorded and reported by transient evoked emission through otoacoustic emissions assessment which included participants with presence of transient evoked emissions from frequencies 1000 Hz to 4000 Hz at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Distort Product Through Otoacoustic Emissions Assessment
Audiological evaluations of participants were recorded and reported by distort product through otoacoustic emissions assessment which included participants with presence of distort product at frequencies ranged from 2000 Hz to 8000 Hz at month 12 and 24. Distortion-product otoacoustic emissions (DPOAEs) are generated in the cochlea in response to two tones of a given frequency and sound pressure level presented in the ear canal. Distort product otoacoustic emissions are an objective indicator of normally functioning cochlea outer hair cells. In this outcome measure, data have been reported for right and left ear separately.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Deaths
An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. AEs included both serious and all non-serious AEs.
Measured: up to 24 months after end of study treatment in Part A (maximum up to 26 months)
Part B: Neurological Progress of Participants as Assessed by the Neurology Optimality Score
The Hammersmith Infant Neurological Examination (HINE) was a standard scoring examination to assess development of cranial nerve; posture; movement; tone; and reflexes and reaction. HINE exam global score is a sum of subset (cranial nerve, posture, movement, tone, reflexes and reactions) scores, ranged from 0 to 78, where higher score represents better outcome. Here, the HINE global scores were reported at month 12 and 24.
Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2012 (estimated)
- Study start5 Aug 2013
- Primary completion17 Oct 2018
- Study completion28 Sep 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Pulmonary Hypertension, Familial Persistent, of the NewbornStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 59 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01720524
- Sponsor's protocol ID
- A1481316
- Other IDs
- 2012-002619-24
- Status last verified
- Aug 2021
- First submitted
- 17 Sep 2012
- Last updated
- 16 Aug 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Publications
Pierce CM, Zhang MH, Jonsson B, Iorga D, Cheruvu N, Balagtas CC, Steinhorn RH. Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial. J Pediatr. 2021 Oct;237:154-161.e3. doi: 10.1016/j.jpeds.2021.05.051. Epub 2021 May 27.
PubMed 34052232
Study at a glance
From the registry record, last updated by the sponsor on 16 Aug 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT
- ClinicalTrials.gov ID
- NCT01720524
- Acronym / sponsor ID
- A1481316
- Keywords
- persistent pulmonary hypertension, newborn, neonates, iv sildenafil, hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 59 participants (actual)
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Industry (pharma, biotech, devices)
- Study start
- 5 Aug 2013 (actual)
- Primary completion
- 17 Oct 2018 (actual)
- Study completion
- 28 Sep 2020 (actual)
- First posted
- 2 Nov 2012 (estimated)
- Results
- Posted 25 Mar 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| placebo | Placebo comparator | Drug: placeboiv placebo of normal saline or 10% dextrose |
| sildenafil | Experimental | Drug: iv sildenafilActive study drug |
Who may qualify
- Ages
- 0 to 4 days
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Neonates with persistent pulmonary hypertension of the newborn
- Age <=96 hours and >=34 weeks gestational age
- Oxygenation Index >15 and <60
- Concurrent treatment with inhaled nitric oxide and >=50% oxygen
Key exclusion criteria (4 listed)
- Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation
- Expected duration of mechanical ventilation <48 hours
- Profound hypoxemia
- Life-threatening or lethal congenital anomaly
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| placeboIV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight. | Drug | placebo |
| iv sildenafilAlso: revatioloading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days. | Drug | sildenafil |
Primary outcome
Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure
Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.
Treatment Failure Rate
Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Treatment failure rate was defined as percentage of participants who needed additional treatment targeting PPHN, needed ECMO, or died during the study.
30 secondary outcomes
Time From Initiation of Intravenous (IV) Study Drug to Final Weaning of Mechanical Ventilation
Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Time From Initiation of Intravenous (IV) Study Drug to First Treatment Failure
Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Percentage of Participants With Individual Components of Treatment Failure
Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Change From Baseline in Oxygenation Index (OI) at Hours 6, 12 and 24 Post-Infusion
Time frame: Baseline, Hours 6, 12 and 24 after start of infusion
Change From Baseline in Differential Saturation at Hours 6, 12 and 24 Post-Infusion
Time frame: Baseline, Hours 6, 12 and 24 after start of infusion
Change From Baseline in Ratio of Partial Pressure of Oxygen in Arterial Blood to Fraction of Inspired Oxygen (P/F) at Hours 6, 12 and 24
Time frame: Baseline, Hours 6, 12 and 24 after start of infusion
Maximum Plasma Concentration (Cmax) of Sildenafil and Its Metabolite
Time frame: Loading dose, Day 1: prior to the start of infusion, 5, 30 minutes after end of loading infusion; Maintenance dose: 48 to 72, 96 to 120 hours during infusion and immediately prior to end of maintenance infusion (up to maximum on Day 14)
Total Plasma Clearance (CL) of Sildenafil and Its Metabolite
Time frame: Loading dose: prior to the start of infusion, 5, 30 minutes after end of loading infusion on Day 1; Maintenance dose: between 48 to 72, 96 to 120 hours during infusion and immediately prior to end of infusion on Day 1
Central Volume of Distribution (Vc) of Sildenafil and Its Metabolite
Time frame: Loading dose: prior to the start of infusion, 5, 30 minutes after end of loading infusion on Day 1; Maintenance dose: between 48 to 72, 96 to 120 hours during infusion and immediately prior to end of infusion on Day 1
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to 31 days after end of study drug infusion (up to 45 days)
Number of Treatment-Emergent Adverse Events (AEs) According to Severity
Time frame: Baseline up to 31 days after end of study drug infusion (up to 45 days)
Number of Participants With Laboratory Abnormalities
Time frame: Up to 14 days from initiation of study drug infusion
Part B: Composite Scores of Cognitive, Language, and Motor Developmental Progress of Participants as Assessed by Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Composite Scores of Social-Emotional and Adaptive Behavior Questionnaire as Assessed by Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)
Time frame: Month 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Number of Participants With Eye Movement Disorders as Assessed by Eye Examination
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Visual Acuity of Verbal Participants as Assessed by Ophthalmological Assessment
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Visual Acuity of Non-Verbal Participants as Assessed by Ophthalmological Assessment
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Visual Acuity of Verbal Participants as Assessed by LogMAR Through Visual Acuity Chart
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Visual Status of Participants With Abnormality as Assessed by Eye Examination of the Anterior and Posterior Segments
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Behavior Hearing Assessment Through Pure Tone Audiometry Test
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Bone Conduction Through Pure Tone Audiometry Test
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Air Conduction Via Phones/Headphones Through Pure Tone Audiometry Test
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Air Conduction Via Soundfield Through Pure Tone Audiometry Test
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Tympanometry Assessment (Peak Pressure) Through Immittance Audiometry Test
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Tympanometry Assessment (Static Acoustic Admittance) Through Immittance Audiometry Test
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Ipsilateral Stapedial Reflex Through Immittance Audiometry Test
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Transient Evoked Emission Through Otoacoustic Emissions Assessment
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Distort Product Through Otoacoustic Emissions Assessment
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Deaths
Time frame: up to 24 months after end of study treatment in Part A (maximum up to 26 months)
Part B: Neurological Progress of Participants as Assessed by the Neurology Optimality Score
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Aug 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 34052232Pierce CM, Zhang MH, Jonsson B, Iorga D, Cheruvu N, Balagtas CC, Steinhorn RH. Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial. J Pediatr. 2021 Oct;237:154-161.e3. doi: 10.1016/j.jpeds.2021.05.051. Epub 2021 May 27.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Pulmonary Hypertension, Familial Persistent, of the Newborn
Recruiting
Effect of Melatonin on Pulmonary Hypertension in Full Term Neonates
Congenital Peumonia, Persistent Pulmonary Hypertension of Newborn
Not yet recruitingObservational study
Post Market Clinical Follow-up to Assess the Portable Nitric Oxide Generation and Delivery System (INOwill N200) for the Treatment of Neonatal Hypoxic Respiratory Failure Complicated by Pulmonary Hypertension
Persistent Pulmonary Hypertension of the Newborn, Hypoxic Respiratory Failure
Recruiting
Close Loop Smart Weaning for INO With PPHN
Persistent Pulmonary Hypertension of the Newborn, Inhaled Nitric Oxide
Active, not recruiting
Preductal Oxygen Saturation Target in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure or Pulmonary Hypertension
Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure
RecruitingObservational study
PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn
Persistent Pulmonary Hypertension of the Newborn
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
42 sites in 12 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing iv sildenafil in people with Pulmonary Hypertension, Familial Persistent, of the Newborn, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 42 sites in 12 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 42 sites in United States, France, United Kingdom, Belgium, Denmark and 7 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 25 Mar 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure (time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01720524, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Aug 2021.